Applicants: Adam J. Katz, et al. U.S. Serial No. 09/936,665 Filed: September 10, 2001 Page 2 of 7

## In the claims:

Please cancel claims 140-143 without prejudice to pursue the subject matter of these claims in a continuation application to be filed in the future.

Please amend claims 1-7 as follows:

(CURRENTLY AMENDED) An isolated adipose-derived stem cell which is substantially free of mature adipocytes and which that can differentiate into two or more developmental phenotypes selected from the group consisting of adipogenic, chondrogenic, cardiogenic, dermategenic, hematepoetic, hematepoe

(CURRENTLY AMENDED) A substantially homogeneous population of adipose-derived stem cells, comprising a plurality of the stem cell of claim 1, 147 or 148. --

(CURRENTLY AMENDED) The adipose-derived stem cell of claim 1, 147 or 148 or the population of claim 2 which can be cultured for at least 15 passages without differentiating. --

(CURRENTLY AMENDED) The adipose-derived stem cell of claim 1, 147 or 148 or the population of claim 2 which is human. --

Applicants: Adam J. Katz, et al. U.S. Serial No. 09/936,665 Filed: September 10, 2001 Page 3 of 7

Li i

(CURRENTLY AMENDED) The cell of any of claims 1, 147 or 148 -4, which is genetically modified. --

(CURRENTLY AMENDED) The cell of any of claims 1, 147 or 148 -5, which has a cell-surface bound intercellular signaling moiety. --

(CURRENTLY AMENDED) The cell of na of claims 1, 147 or 148 -5, which secretes a hormone. —

--139. (New) An isolated, adipose-derived multipotent cell that differentiates into cells of two or more mesodermal phenotypes. --

NEW) An isolated adipose-derived stem cell that differentiates into two or more of the group consisting of a fat cell, a bone cell, a cartilage cell, a nerve cell, and a muscle cell.

--148. (NEW) An isolated adipose-derived stem cell that differentiates into a combination of any of a fat cell, a bone cell, a cartilage cell, a nerve cell, or a muscle cell. --

## REMARKS

Claims 1-7 and 139-146 are pending in the subject application. In the March 11 Office Action, the Patent Office states that claims 5-7 stand as non-examined, and claims 144-146 are withdrawn. Applicants have amended claims 1-7 herein, and added new claims 147-148 above. Applicants also cancel claims 140-143 herein.

Accordingly, claims 1-7 and 139 are pending and being examined.